CRISPR Therapeutics reiterated its plan to pursue the highest dose for its lipid-lowering gene editing therapy, citing mixed durability results a year after dosing in early-stage data presented at the European Society of Cardiology meeting. The company’s approach reflects a dose-escalation strategy intended to clarify durability and benefit. Separately, Aprea Therapeutics expanded its Phase I trial of APR-1051, a WEE1 kinase inhibitor in DNA damage response biology. The company accelerated enrollment, increased active clinical sites, and broadened development into uterine serous carcinoma and Cyclin E–overexpressing platinum-resistant ovarian cancer, plus combination arms in HPV-positive head and neck and colorectal cancers. Together, the updates show active protocol widening and dose strategy refinement to generate faster mechanistic and efficacy evidence.